These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1056 related items for PubMed ID: 18163551

  • 21. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
    Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S, Fukushima M.
    Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
    [Abstract] [Full Text] [Related]

  • 22. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
    Lee J, Kim SJ, Choi H, Kim YH, Lim IT, Yang HM, Lee CS, Kang HR, Ahn SK, Moon SK, Kim DH, Lee S, Choi NS, Lee KJ.
    J Med Chem; 2010 Sep 09; 53(17):6337-54. PubMed ID: 20690624
    [Abstract] [Full Text] [Related]

  • 23. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
    Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F.
    Cancer Res; 2002 Sep 15; 62(18):5344-50. PubMed ID: 12235005
    [Abstract] [Full Text] [Related]

  • 24. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
    Radi M, Adema AD, Daft JR, Cho JH, Hoebe EK, Alexander LE, Peters GJ, Chu CK.
    J Med Chem; 2007 May 03; 50(9):2249-53. PubMed ID: 17419604
    [Abstract] [Full Text] [Related]

  • 25. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D, Okamura M, Yoshimi H, Yamori T.
    Eur J Cancer; 2009 Mar 03; 45(5):857-65. PubMed ID: 19144509
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.
    Cancer Chemother Pharmacol; 2008 Nov 03; 62(6):1045-54. PubMed ID: 18301895
    [Abstract] [Full Text] [Related]

  • 27. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
    Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L.
    Cancer Res; 1999 Nov 15; 59(22):5751-7. PubMed ID: 10582695
    [Abstract] [Full Text] [Related]

  • 28. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.
    Clin Cancer Res; 2001 May 15; 7(5):1429-37. PubMed ID: 11350914
    [Abstract] [Full Text] [Related]

  • 29. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
    Jain M, Fan J, Baturay NZ, Kwon CH.
    J Med Chem; 2004 Jul 15; 47(15):3843-52. PubMed ID: 15239662
    [Abstract] [Full Text] [Related]

  • 30. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
    Helsby NA, Atwell GJ, Yang S, Palmer BD, Anderson RF, Pullen SM, Ferry DM, Hogg A, Wilson WR, Denny WA.
    J Med Chem; 2004 Jun 03; 47(12):3295-307. PubMed ID: 15163209
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, Denny WA.
    J Med Chem; 2007 Mar 22; 50(6):1197-212. PubMed ID: 17326614
    [Abstract] [Full Text] [Related]

  • 32. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J.
    Clin Cancer Res; 2004 Nov 01; 10(21):7382-91. PubMed ID: 15534115
    [Abstract] [Full Text] [Related]

  • 33. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP, Anderson RF, Ferry DM, Wilson WR, Denny WA.
    J Med Chem; 2003 Dec 04; 46(25):5533-45. PubMed ID: 14640560
    [Abstract] [Full Text] [Related]

  • 34. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, Yarranton GT, Buckman D, Roscoe W, Zhou F, Salles A, Chen TH, Horgan K, Wang YH, Nguyen T, Bebbington CR.
    Cancer Res; 2003 Sep 01; 63(17):5526-31. PubMed ID: 14500390
    [Abstract] [Full Text] [Related]

  • 35. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
    Fang L, Zhang G, Li C, Zheng X, Zhu L, Xiao JJ, Szakacs G, Nadas J, Chan KK, Wang PG, Sun D.
    J Med Chem; 2006 Feb 09; 49(3):932-41. PubMed ID: 16451059
    [Abstract] [Full Text] [Related]

  • 36. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.
    J Med Chem; 2007 Jun 14; 50(12):2767-78. PubMed ID: 17488003
    [Abstract] [Full Text] [Related]

  • 37. Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy.
    Sbovata SM, Bettio F, Mozzon M, Bertani R, Venzo A, Benetollo F, Michelin RA, Gandin V, Marzano C.
    J Med Chem; 2007 Sep 20; 50(19):4775-84. PubMed ID: 17713897
    [Abstract] [Full Text] [Related]

  • 38. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, Shochat D, Yarranton GT, Trouet A.
    Cancer Res; 2002 Apr 15; 62(8):2327-31. PubMed ID: 11956091
    [Abstract] [Full Text] [Related]

  • 39. A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
    Leese MP, Hejaz HA, Mahon MF, Newman SP, Purohit A, Reed MJ, Potter BV.
    J Med Chem; 2005 Aug 11; 48(16):5243-56. PubMed ID: 16078843
    [Abstract] [Full Text] [Related]

  • 40. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.
    Cancer Chemother Pharmacol; 2009 Jan 11; 63(2):201-12. PubMed ID: 18350296
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.